BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31014710)

  • 1. Changes in Retinal Thickness on OCT from Intravitreal Melphalan.
    Narala R; Kim JW; Lang P; Le BHA; Hendargo HC; Branco D; Berry JL
    Ophthalmol Retina; 2019 Mar; 3(3):288-289. PubMed ID: 31014710
    [No Abstract]   [Full Text] [Related]  

  • 2. Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma.
    Panthagani J; Montecinos P; López JP; Parulekar M
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28348. PubMed ID: 32634267
    [No Abstract]   [Full Text] [Related]  

  • 3. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
    Chao A; Kao LY; Liu L; Wang NK
    BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERG and OCT abnormalities in retinoblastoma after melphalan intravitreous injection.
    Albuquerque ML; Moreto R; Bergamo M; Corrêa ZM; Jorge R
    Arq Bras Oftalmol; 2022; 87(1):0037. PubMed ID: 35857974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
    Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
    Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma.
    Hsieh T; Liao A; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
    PLoS One; 2020; 15(7):e0235016. PubMed ID: 32609726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
    Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
    Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
    Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
    Xue K; Ren H; Meng F; Zhang R; Qian J
    BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
    Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
    Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
    [No Abstract]   [Full Text] [Related]  

  • 11. Exudative Retinal Detachment Following Intravitreal Chemotherapeutic Treatment for Retinoblastoma.
    Kotlyar B; Shapiro M; Blair M
    Ophthalmic Surg Lasers Imaging Retina; 2019 Apr; 50(4):248-252. PubMed ID: 30998248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
    Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
    Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
    Ghassemi F; Shields CL
    Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
    Smith SJ; Smith BD; Mohney BG
    Br J Ophthalmol; 2014 Mar; 98(3):292-7. PubMed ID: 24187047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
    Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
    J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal vascular precipitates during administration of melphalan into the ophthalmic artery.
    Superstein R; Lederer D; Dubois J; Hamel P; Carret AS; Callejo S
    JAMA Ophthalmol; 2013 Jul; 131(7):963-5. PubMed ID: 23846208
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravitreal injection of melphalan in the treatment of retinoblastoma with vitreous cavity seeding.
    Sun YB; Hui P; Punyara K; Bi MC; Li SH; Teng SY; Song E
    Chin Med J (Engl); 2013; 126(8):1587. PubMed ID: 23595400
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed Cerebral Infarction Following Intra-arterial Chemotherapy for Retinoblastoma.
    De la Huerta I; Seider MI; Hetts SW; Damato BE
    JAMA Ophthalmol; 2016 Jun; 134(6):712-4. PubMed ID: 27077487
    [No Abstract]   [Full Text] [Related]  

  • 19. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma.
    Francis JH; Marr BP; Brodie SE; Gobin YP; Abramson DH
    JAMA Ophthalmol; 2014 Aug; 132(8):1024-5. PubMed ID: 25124953
    [No Abstract]   [Full Text] [Related]  

  • 20. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.
    Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH
    Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.